These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19712865)

  • 41. ERBB2 status and outcome of endocrine treatment.
    Miller WR
    Lancet Oncol; 2008 Jan; 9(1):4-5. PubMed ID: 18177812
    [No Abstract]   [Full Text] [Related]  

  • 42. Adjuvant aromatase inhibitors: are we there yet?
    Fleming GF
    Cancer; 2003 Nov; 98(9):1779-81. PubMed ID: 14584057
    [No Abstract]   [Full Text] [Related]  

  • 43. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Letrozole in advanced breast cancer: the PO25 trial.
    Mouridsen HT
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):19-29. PubMed ID: 17333340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM
    Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 47. [National Conference of Medical Oncology. Controversies in the treatment of breast cancer. Genova, October 28, 2000].
    Longo F
    Tumori; 2000; 86(6):A13-8. PubMed ID: 11271674
    [No Abstract]   [Full Text] [Related]  

  • 48. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
    Herold CI; Blackwell KL
    Breast; 2008 Jan; 17 Suppl 1():S15-24. PubMed ID: 18279763
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
    Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
    Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Chlebowski RT; Col N
    J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
    [No Abstract]   [Full Text] [Related]  

  • 52. Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
    Michaud LB
    Drugs; 2006; 66(3):363-4. PubMed ID: 16526827
    [No Abstract]   [Full Text] [Related]  

  • 53. Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    DeGrendele H
    Clin Breast Cancer; 2003 Dec; 4(5):311-2. PubMed ID: 14715105
    [No Abstract]   [Full Text] [Related]  

  • 54. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toremifene and letrozole for advanced breast cancer.
    Med Lett Drugs Ther; 1998 Apr; 40(1024):43-5. PubMed ID: 9580744
    [No Abstract]   [Full Text] [Related]  

  • 56. Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
    Berruti A; Tucci M; Mosca A; Vana F; Ardine M; Dogliotti L; Angeli A; Bertoldo F
    J Clin Oncol; 2007 Apr; 25(11):1455-6. PubMed ID: 17416873
    [No Abstract]   [Full Text] [Related]  

  • 57. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
    Aapro M; van de Velde CJ; Markopoulos C; Bartlett JM; Putter H; Coleman RE
    Breast; 2013 Aug; 22(4):488-94. PubMed ID: 23454040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.